Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s00894-020-04600-4 http://scihub22266oqcxt.onion/10.1007/s00894-020-04600-4 33184722!7661016!33184722     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Mol+Model 2020 ; 26 (12): 340 Nephropedia Template TP {{tp|p=33184722|t=2020. Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA |pdf=|usr=}}{{33184722}} gab.com Text Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA JO: J Mol Model http://www.kidney.de/pget.php?&tw=1&pmid=33184722 #FOAvip Among targets selected for studies aimed at identifying potential inhibitors against COVID-19, SARS-CoV2 main proteinase (M(pro)) is highlighted. M(pro) is indispensable for virus replication and is a promising target of potential inhibitors of COVID-19. Recently, monomeric SARS-CoV2 M(pro), drug repurposing, and docking methods have facilitated the identification of several potential inhibitors. Results were refined through the assessment of dimeric SARS-CoV2 M(pro), which represents the functional state of enzyme. Docking and molecular dynamics (MD) simulations combined with molecular mechanics/generalized Born surface area (MM/GBSA) studies indicated that dimeric M(pro) most significantly impacts binding affinity tendency compared with the monomeric state, which suggests that dimeric state is most useful when performing studies aimed at identifying drugs targeting M(pro). In this study, we extend previous research by performing docking and MD simulation studies coupled with an MM/GBSA approach to assess binding of dimeric SARS-CoV2 M(pro) to 12 FDA-approved drugs (darunavir, indinavir, saquinavir, tipranavir, diosmin, hesperidin, rutin, raltegravir, velpatasvir, ledipasvir, rosuvastatin, and bortezomib), which were identified as the best candidates for the treatment of COVID-19 in some previous dockings studies involving monomeric SARS-CoV2 M(pro). This analysis identified saquinavir as a potent inhibitor of dimeric SARS-CoV2 M(pro); therefore, the compound may have clinical utility against COVID-19. Graphical abstract. Twit Text FOAVip Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA ????J Mol Model http://www.kidney.de/pget.php?&tw=1&pmid=33184722 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33184722 #FOAvip English Wikipedia <ref>{{Cite pmid|33184722}}</ref> Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA #MMPMID33184722 Bello M; Martinez-Munoz A; Balbuena-Rebolledo I J Mol Model 2020[Nov]; 26 (12): 340 PMID33184722show ga Among targets selected for studies aimed at identifying potential inhibitors against COVID-19, SARS-CoV2 main proteinase (M(pro)) is highlighted. M(pro) is indispensable for virus replication and is a promising target of potential inhibitors of COVID-19. Recently, monomeric SARS-CoV2 M(pro), drug repurposing, and docking methods have facilitated the identification of several potential inhibitors. Results were refined through the assessment of dimeric SARS-CoV2 M(pro), which represents the functional state of enzyme. Docking and molecular dynamics (MD) simulations combined with molecular mechanics/generalized Born surface area (MM/GBSA) studies indicated that dimeric M(pro) most significantly impacts binding affinity tendency compared with the monomeric state, which suggests that dimeric state is most useful when performing studies aimed at identifying drugs targeting M(pro). In this study, we extend previous research by performing docking and MD simulation studies coupled with an MM/GBSA approach to assess binding of dimeric SARS-CoV2 M(pro) to 12 FDA-approved drugs (darunavir, indinavir, saquinavir, tipranavir, diosmin, hesperidin, rutin, raltegravir, velpatasvir, ledipasvir, rosuvastatin, and bortezomib), which were identified as the best candidates for the treatment of COVID-19 in some previous dockings studies involving monomeric SARS-CoV2 M(pro). This analysis identified saquinavir as a potent inhibitor of dimeric SARS-CoV2 M(pro); therefore, the compound may have clinical utility against COVID-19. Graphical abstract. |Antiviral Agents/chemistry/*pharmacology[MESH] |Betacoronavirus/*drug effects/enzymology[MESH] |COVID-19[MESH] |Coronavirus 3C Proteases[MESH] |Coronavirus Infections/*drug therapy/virology[MESH] |Cysteine Endopeptidases[MESH] |Drug Repositioning[MESH] |Humans[MESH] |Molecular Docking Simulation[MESH] |Molecular Dynamics Simulation[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/virology[MESH] |Protease Inhibitors/chemistry/*pharmacology[MESH] |Protein Multimerization[MESH] |SARS-CoV-2[MESH] |Saquinavir/chemistry/*pharmacology[MESH]Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV(epmc).pdf DeepDyve Pubget Overpricing